COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
Healthy adults over 18 years old that are attending the hospital with signs and symptoms of coronavirus infection can participate in the study. The study involves samples being taken at day 0 (consent
Sponsors
Liverpool School of Tropical Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults 18 years old 2. Presenting with any of the following COVID-19 symptoms 2.1 Fever =37.8°C +/- 2.2. Shortness of breath +/- 2.3. New/ persistent cough 2.4 Clinical or radiological evidence of pneumonia 3. Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement 4. Capacity to give informed verbal consent
Exclusion criteria
Exclusion criteria: 1. Lack of capacity or unable to perform verbal consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Pneumococcal colonisation measured in SARS-CoV-2-positive participants and SARS-CoV-2-negative controls by PCR at baseline, day 2, day 7 and day 28 2. SARS-CoV-2 is detected and quantified by RT-qPCR in NP swabs at baseline, day 2, day 7 and day 28 (for the SARS-CoV-2-positive participants) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Levels of inflammation are assessed by levels of 30 cytokines in nasal fluid and serum at baseline, day 2, day 7 and day 28 2. T-cell and B-cell antigen-specific responses are measured by flow cytometry based assays using PBMCS at baseline, day 2, day 7 and day 28 3. Antibody responses against SARS-CoV-2 are measured by ELISA at baseline, day 2, day 7 and day 28 4. Cellular immune responses to SARS-CoV-2 are measured by flow cytometry and functional assays in BAL samples collected at 3 - 6 months and 9 - 12 months (in both SARS-CoV-2-positive participants and SARS-CoV-2-negative controls) | — |
Countries
England, United Kingdom
Contacts
Public ContactAngela Hyder-Wright
Outcome results
None listed